Cargando…

CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes

Cystic fibrosis (CF) is caused by mutations in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene. The combination of the CFTR modulators elexacaftor, tezacaftor, and ivacaftor (ETI) enables the effective rescue of CFTR function in people with the most prevalent F508del mutation. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lefferts, Juliet W., Bierlaagh, Marlou C., Kroes, Suzanne, Nieuwenhuijze, Natascha D. A., Sonneveld van Kooten, Heleen N., Niemöller, Paul J., Verburg, Tibo F., Janssens, Hettie M., Muilwijk, Danya, van Beuningen, Sam F. B., van der Ent, Cornelis K., Beekman, Jeffrey M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572896/ https://www.ncbi.nlm.nih.gov/pubmed/37833986 http://dx.doi.org/10.3390/ijms241914539

Ejemplares similares

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
por: Tümmler, Burkhard
Publicado: (2023)

Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
por: Bacalhau, Mafalda, et al.
Publicado: (2023)

Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator
por: Laselva, Onofrio, et al.
Publicado: (2021)

Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
por: Veit, Guido, et al.
Publicado: (2020)

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators
por: Muilwijk, Danya, et al.
Publicado: (2021)

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
por: Zhang, Lijia, et al.
Publicado: (2022)

Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation
por: Roder, Lauren, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
por: Tsai, Alice, et al.
Publicado: (2020)

Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment
por: Shaughnessy, Ciaran A., et al.
Publicado: (2021)

ICER releases evidence report on elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2020)

Optimism with Caution: Elexacaftor–Tezacaftor–Ivacaftor in Patients with Advanced Pulmonary Disease
por: Kuek, Stephanie L., et al.
Publicado: (2021)

Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19?
Publicado: (2022)

Elexacaftor–Tezacaftor–Ivacaftor improves exercise capacity in adolescents with cystic fibrosis
por: Causer, Adam J., et al.
Publicado: (2022)

Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis
por: Cavinato, Luca, et al.
Publicado: (2023)

Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants
por: Borgo, Christian, et al.
Publicado: (2022)

383: Cystic fibrosis macrophage function after elexacaftor/tezacaftor/ivacaftor initiation
por: Zhang, S., et al.
Publicado: (2021)

THE IMPACT OF TRIKAFTA (ELEXACAFTOR/IVACAFTOR/TEZACAFTOR) ON PATIENTS WITH CYSTIC FIBROSIS WITH COVID-19
por: MILES, B., et al.
Publicado: (2022)

Elexacaftor/Tezacaftor/Ivacaftor Accelerates Wound Repair in Cystic Fibrosis Airway Epithelium
por: Laselva, Onofrio, et al.
Publicado: (2022)

Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome
por: Pallenberg, Sophia T., et al.
Publicado: (2022)

The effect of elexacaftor/tezacaftor/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis
por: Allgood, Sarah, et al.
Publicado: (2023)

Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
por: Piehler, Linus, et al.
Publicado: (2023)

A new era for people with cystic fibrosis
por: Bierlaagh, Marlou C., et al.
Publicado: (2021)

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial
por: Nichols, David P., et al.
Publicado: (2021)

Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment
por: Shaughnessy, Ciaran A., et al.
Publicado: (2021)

Change in Lung Function after Initiation of Elexacaftor–Tezacaftor–Ivacaftor: Do Not Forget Anatomy!
por: Martin, Clémence, et al.
Publicado: (2022)

Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy
por: Westhölter, Dirk, et al.
Publicado: (2023)

Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor–Tezacaftor–Ivacaftor
por: Patel, Payal, et al.
Publicado: (2023)

Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
por: Gramegna, Andrea, et al.
Publicado: (2023)

Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
por: Kapouni, Nikoletta, et al.
Publicado: (2023)

Triple Therapy for Cystic Fibrosis (Elexacaftor, Tezacaftor, and Ivacaftor): Desensitization After Skin Rash
por: Santos, Ana Isabel, et al.
Publicado: (2023)

The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs
por: Sondo, Elvira, et al.
Publicado: (2022)

Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients
por: Kos, Renate, et al.
Publicado: (2022)

Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor/Tezacaftor/Ivacaftor (Kaftrio)
por: Salehi, Mahan, et al.
Publicado: (2021)

Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
por: Comegna, Marika, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
por: Choong, Eva, et al.
Publicado: (2022)

Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis
por: Stekolchik, Elena, et al.
Publicado: (2022)

The Impact of Elexacaftor/Ivacaftor/Tezacaftor on Cystic Fibrosis Patients Who Acquire COVID-19 Infection
por: Miles, Brittany, et al.
Publicado: (2022)

Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapy
por: Martin, Christian, et al.
Publicado: (2023)

Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity
por: Schütz, Katharina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_81bb4hav0nqaqi7v2agc8pt761